PL
VRTX icon

Parkwood LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Parkwood LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,324
Closed -$201K – 258
2017
Q3 		$201K Sell
1,324
-1,163
-47% -$175K 0.03% 208
2017
Q2 		$320K Buy
+2,487
New +$299K 0.05% 275
2015
Q3 		– Sell
-5,427
Closed -$670K – 563
2015
Q2 		$670K Hold
5,427
– – 0.09% 140
2015
Q1 		$640K Hold
5,427
– – 0.08% 149
2014
Q4 		$645K Buy
5,427
+2,048
+61% +$231K 0.09% 127
2014
Q3 		$379K Buy
+3,379
New +$322K 0.08% 180
2014
Q1 		– Sell
-1,303
Closed -$97K – 430
2013
Q4 		$97K Buy
+1,303
New +$90.7K 0.02% 501

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Parkwood LLC's VRTX Position: Q4 2017 in Review

Parkwood LLC sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 1,324 shares — an estimated $201K sold.

Parkwood LLC first reported a position in VRTX in Q4 2013 and held it in 7 quarters. The position peaked at $670K in Q2 2015. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Parkwood LLC reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Parkwood LLC sold 1,324 Vertex Pharmaceuticals shares in Q4 2017, an estimated $201K.
  • Parkwood LLC first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 7 quarters.
  • Parkwood LLC's Vertex Pharmaceuticals position peaked at $670K in Q2 2015.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Parkwood LLC's 13F filing for Q4 2017, filed 8 Feb 2018.